Kaleido Biosciences and CoreBiome Partner to Accelerate Microbiome Therapeutic Development
– Agreement will increase productivity and speed of Kaleido’s clinical development programs
BEDFORD, Mass, October 10, 2017 — Kaleido Biosciences, a clinical-stage biotechnology company developing novel chemistries to unlock the power of the human microbiome, today announced an agreement with CoreBiome, a genomics platform company focused on accelerating microbiome innovation with expert genomics and big-data analytics, to provide high-scale and high-content microbiome data to increase the speed and productivity of Kaleido’s clinical development and discovery programs.
Under the terms of this agreement, Kaleido has committed that over the next 12 months, CoreBiome will conduct its proprietary BoosterShot shotgun sequencing service on tens of thousands of microbiome samples from Kaleido’s recently completed and ongoing clinical studies, in addition to samples from their proprietary screening platform. The data from this collaboration combines with physiological data, metabolomics, and high-throughput screening assays to enable deep insights into how Kaleido’s chemistries invoke changes in microbiome function.
“The industry standard for microbiome profiling to date has been 16S rRNA sequencing, however at Kaleido, we have found that 16S leaves many questions unanswered,” said Geoffrey von Maltzahn, co-founder and President of Kaleido Biosciences. “The BoosterShot platform enables us to better resolve individual bacterial species, and additionally it provides us with valuable information to decode functional signals. Corebiome’s technology plays a significant role in our overall computational biology program and is helping us resolve structure-activity relationships and design novel, specific and highly effective compounds to modulate microbiomes in a variety of applications.”
“We are enthusiastic about our partnership with Kaleido Biosciences to accelerate their innovative clinical development programs,” said Dan Knights, co-founder and CEO of CoreBiome. “This partnership represents a validation of our mission at CoreBiome. By integrating cutting-edge genomics and informatics, we can help our partners rapidly scale their microbiome discovery process so they can get products to market faster.”
About Kaleido Biosciences:
Kaleido Biosciences is a clinical-stage biotechnology company engaged in the development of novel chemistries that unlock the power of the microbiome to revolutionize health. The Company has built the first R&D engine to systematically create, discover, and develop interventions that activate metabolic processes in the microbiome to treat disease and maintain health. Since its founding in 2015 by Flagship VentureLabs, Kaleido has advanced candidate products into clinical studies across programs in rare genetic diseases, oncology and infectious disease, and has generated more than 3,000 days of human clinical data. The Company is also creating consumer products that optimize the microbiome’s natural roles in promoting health.
CoreBiome is a genomics platform company focused on accelerating discovery for customers in the pharmaceutical, agriculture, and research communities, to unleash the translational potential of the microbiome. The Company’s proprietary BenchMarkTM, BoosterShotTM, BoostArrayTM, and Core AnalysisTM platforms provide a rapid, affordable, and highly accurate measurement and interpretation of microbial diversity. Founded in 2016 based on intellectual property originating from the University of Minnesota, CoreBiome has rapidly moved from concept stage to full commercialization with the assistance of a seed funding round.